Will AbbVie's Neuroscience Segment Continue to Aid Top Line in 2026?

Core Insights - AbbVie reported strong fourth-quarter and full-year 2025 results, with significant revenue growth driven by its immunology portfolio and steady contributions from its neuroscience segment [1][2]. Neuroscience Segment Performance - The neuroscience segment generated $10.8 billion in revenue for 2025, accounting for approximately 18% of AbbVie's total revenues, reflecting a nearly 20% year-over-year increase [2][8]. - Key products in this segment, including Botox Therapeutic, Vraylar, Qulipta, and Ubrelvy, experienced double-digit sales growth, while the newer therapy Vyalev contributed $482 million in sales [2][8]. - For 2026, AbbVie anticipates neuroscience revenues to reach $12.5 billion, indicating a 16% growth from 2025, with expectations for Vyalev to exceed $1 billion in global sales [3][8]. Product Pipeline and Future Growth - AbbVie is preparing to expand its neuroscience portfolio with a new oral therapy for Parkinson's disease, tavapadon, which is currently under FDA review [4]. - If approved, tavapadon could enhance AbbVie's presence in the Parkinson's disease market and strengthen the long-term growth potential of its neuroscience segment [4]. Competitive Landscape - Competitors in the neuroscience space include Biogen and Johnson & Johnson, both of which are also focusing on expanding their neuroscience offerings [5][6]. - Biogen is diversifying its portfolio due to declining revenues in its multiple sclerosis franchise, while Johnson & Johnson continues to grow its neuroscience products through acquisitions and new therapies [5][6]. Valuation and Market Performance - AbbVie shares are currently trading at a price/earnings (P/E) ratio of 15.61, which is below the industry average of 18.26, although above its five-year mean of 13.73 [9]. - The Zacks Consensus Estimate for AbbVie's 2026 EPS has increased from $14.31 to $14.54, indicating positive market sentiment [11].